Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 5 - Drugs for disorders of the endocrine system
Patents for A61P 5 - Drugs for disorders of the endocrine system (28,908)
10/2003
10/02/2003US20030186894 Dry powder compositions having improved dispersivity
10/02/2003US20030186893 Purified lh
10/02/2003US20030186889 Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using a specific chemokine receptor analysis and the chemokine receptor-ligand interaction
10/02/2003US20030186844 Gherlin analogs
10/02/2003US20030186842 Contacting a cell population with an inhibiting effective amount of a reagent that suppresses the protease activity of at least one member of the interleukin-1beta- converting enzyme (ICE)/CED-3 family
10/02/2003US20030185815 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
10/02/2003US20030185765 Composition for pulmonary administration comprising a drug and a hydrophobic amino acid
10/02/2003CA2479898A1 Novel .alpha.-amino-n-(diaminophosphinyl)lactam derivatives
10/02/2003CA2479880A1 Combination comprising an hmg-coa reductase inhibittor and an insulin secretor enhancer or an insulin sensitizer
10/02/2003CA2479722A1 Combination of an aldosterone receptor antagonist and a fibric acid derivative
10/02/2003CA2479718A1 Analgesics for nasal administration
10/02/2003CA2479671A1 Combination of an aldosterone receptor antagonist and nicotinic acid for a nicotinic acid derivative
10/02/2003CA2479259A1 Combination of an aldosterone receptor antagonist and a bile acid sequestering agent
10/02/2003CA2478974A1 Inhalable sustained therapeutic formulations
10/02/2003CA2478801A1 Method for administration of growth hormone via pulmonary delivery
10/02/2003CA2478327A1 Hgh (human growth hormone) formulations for pulmonary administration
10/02/2003CA2477651A1 Kinase inhibitors
10/01/2003EP1348433A1 Thiazol-2-yl-imine compounds as PDE-7 inhibitors
10/01/2003EP1347980A1 Compounds specific to adenosine-a1,-a2a, and- a3-receptor and uses thereof
10/01/2003EP1347979A1 Indole derivatives and their use as 5-ht2b and 5-ht2c receptor ligands
10/01/2003EP1347959A1 Indole derivatives as ligands of thyroid receptors
10/01/2003EP1347805A2 Pharmaceutical preparation for douches and/or irrigations of natural or pathological cavities in the human body
10/01/2003EP1347751A2 Methods of treating bone cancer and the pain associated therewith using endothelin antagonists
10/01/2003EP1237854B1 Comminuted form of (s)-2-ethoxy -3- 4-(2- 4-methanesulfonyloxyphenyl ethoxy) phenyl] propanoic acid
10/01/2003EP1204655B1 A crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy] phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride
10/01/2003CN1446229A Somatostatin analogues
10/01/2003CN1446218A Benzimidazole derivatives, preparation method and therapeutic use thereof
10/01/2003CN1446217A Beta-carboline derivatives useful as inhibitors of phosphodiesterase
10/01/2003CN1446106A Method of treating estrogen receptor positive carcinoma
10/01/2003CN1446084A Treatment of insulin resistance syndrome
10/01/2003CN1444926A Bio-adhesiveness drug release system
09/2003
09/30/2003US6627660 Stabilized thyroxine compounds
09/30/2003US6627649 (2S)-1-((2R,3S)-5-chloro-3-(2-chlorophenyl)-1-(3,4 -dimethoxybenzenesulfonyl)-3-hydroxy-2,3-dihydro-1H-indole-2 -carbonyl)pyrrolidine-2-carboxamide, a selective V1a arginine vasopressin receptor antagonist, in combination with the
09/30/2003US6627626 Antiinflammation agents and antiarthritic agents colon cancer, and Alzheimer's disease in mammals, preferably humans, dogs, cats and livestock animals.
09/30/2003US6627609 Peptides which contain N-methylated amino acid units and have improved water solubility. Medicaments in which the peptides according to the invention are contained can be used for the treatment of hormone- dependent tumours and
09/30/2003US6627425 Human glucose-6-phosphatase molecules and uses thereof
09/30/2003CA2133759C Evaluation and treatment of patients with progressive immunosuppression
09/30/2003CA2114630C Steroid sulphatase inhibitors
09/25/2003WO2003078435A1 Pyrazolo(1,5-a)pyridine derivatives as neurotransmitter modulators
09/25/2003WO2003078425A1 Novel crystalline form of 5-[4-[[3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl]methoxy]benzyl]thiazolidine-2,4-dione potassium salt
09/25/2003WO2003078404A1 Pyrimidine derivatives
09/25/2003WO2003078398A1 NON-PEPTIDE GnRH ANTAGONISTS
09/25/2003WO2003077949A2 Methods of treating diabetes using pde 11a inhibitors
09/25/2003WO2003077927A1 Sulfatase inhibiting progestogen-only contraceptive regimens
09/25/2003WO2003077904A1 Biological activity-promoting compositions containing soybean germ-origin isoflavone aglycon
09/25/2003WO2003077890A1 Hormone-containing transdermal therapeutic system with an active substance reservoir based on vinylacetate-vinylpyrrolidone copolymer with improved cohesion.
09/25/2003WO2003077847A2 Substituted amides
09/25/2003WO2003077840A2 Method of modulating inflammatory response
09/25/2003WO2003077834A2 Central airway administration for systemic delivery of therapeutics
09/25/2003WO2003011855A3 Pyrazole-derived kinase inhibitors and uses thereof
09/25/2003WO2003006993A3 Gel compositions
09/25/2003WO2002055688A8 Histone deacetylase inhibitors in diagnosis and treatment of thyroid neoplasms
09/25/2003WO2002031146A3 Isolated human nuclear hormone receptors, nucleic acid molecules encoding human nuclear hormone receptors, and uses thereof
09/25/2003WO2002030884A3 Sulfide and disulfide compounds and compositions for cholesterol management and related uses
09/25/2003US20030181728 Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function
09/25/2003US20030181662 Human procalcitonin and the preparation and use thereof
09/25/2003US20030181519 Substituted phenyl naphthalenes as estrogenic agents
09/25/2003US20030181497 Heterocyclic acridone inhibitors of IMPDH enzyme
09/25/2003US20030181481 Therapeutic drugs for treating central nervous system disorders
09/25/2003US20030181458 Preferential serotonin receptors antagonists comprising heterocyclic amines used for prophylaxis or prevention of headaches, sleep, sexual or eating disorders and as antidepressants
09/25/2003US20030181444 Heterocyclic amines such as 4-(3,4-dichlorophenyl)-2-(2-(4-methylpiperazin-1-yl)-benzylidene) -thiomorpholin-3-one, used as antiserotonine agents
09/25/2003US20030181435 Systemic lupus erythematosus therapy
09/25/2003US20030181430 Novel topical oestroprogestational compositions with a systemic effect
09/25/2003US20030181385 The LHRH antagonist comprise a peptide compound, wherein a residue of the peptide compound corresponding to the amino acid at position 6 of natural mammalian LHRH comprises a hydrophilic N- acyl moiety, a dipolar moiety, a sulfonium
09/25/2003US20030180805 Methods and compositions for derepression of IAP-inhibited caspase
09/25/2003US20030180778 UDP-N-acetylglucosamine: galactose-beta1,3-N-acetylgalactosamine-alpha-R/ (GlcNAc to GalNAc) beta1,6-N-acetylglucosaminyltransferase, C2GnT3
09/25/2003US20030180404 Methods of treating clinical diseases with isoflavones
09/25/2003US20030180394 Extracts from sophora species, method for producing the same and their use
09/25/2003US20030180366 Bioadhesive drug delivery system
09/25/2003US20030180364 Catheter injectable depot compositions and uses thereof
09/25/2003US20030180348 Transcellular drug delivery system
09/25/2003US20030180288 Methods and compositions for modulating immune response and for the treatment of inflammatory disease
09/25/2003US20030180231 Cosmetics, skin disorders; sunscreen agents; aging resistance
09/25/2003CA2488928A1 Method of modulating inflammatory response
09/25/2003CA2479212A1 Central airway administration for systemic delivery of therapeutics
09/25/2003CA2478715A1 Novel pyrazolo [1,5-a]pyridine derivatives and their use as neurotransmitter modulators
09/25/2003CA2478713A1 Non-peptide gnrh antagonists
09/25/2003CA2478165A1 Sulfatase inhibiting progestogen-only contraceptive regimens
09/25/2003CA2477832A1 Methods of treating diabetes using pde 11a inhibitors
09/24/2003EP1346065A2 Antisense modulation of src-2 expression
09/24/2003EP1345956A2 Intracellular delivery of biological effectors by novel transporter peptide sequences
09/24/2003EP1345947A1 A new process for preparing fused 1,2,4-thiadiazine derivatives
09/24/2003EP1345938A1 Tricyclic crf receptor antagonists
09/24/2003EP1345929A2 Pyrazole compounds useful as protein kinase inhibitors
09/24/2003EP1345928A2 Pyrazole compounds useful as protein kinase inhibitors
09/24/2003EP1345927A1 Pyrazole compounds useful as protein kinase inhibitors
09/24/2003EP1345926A2 Pyrazole compounds useful as protein kinase inhibitors
09/24/2003EP1345925A2 Pyrazole compounds useful as protein kinase inhibitors
09/24/2003EP1345922A1 Pyrazole compounds useful as protein kinase inhibitors
09/24/2003EP1345914A1 Therapeutic compounds
09/24/2003EP1345895A1 Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
09/24/2003EP1345567A2 Calcium channel transport polynucleotides, polypeptides, and antibodies
09/24/2003EP1080055B1 24-hydroxyvitamin d, analogs and uses thereof
09/24/2003EP0847278B1 Analogs of parathyroid hormone
09/24/2003CN1444597A 2-substituted pregna-1,3,5(10)-triene and chola-1,3,5(10)-triene derivatives and their biological activity
09/24/2003CN1444596A 16 alpha-methyl or ethyl substituted estrogens
09/24/2003CN1444573A Carboxamide compounds and their use as antagonists of human 11CBY receptor
09/24/2003CN1444570A Non-steroidal inflammation inhibitors
09/24/2003CN1444566A Imidazolyl derivatives
09/23/2003US6624200 Deliver of testosterone to the bloodstream of a mammal through a mucosal surface with polycarbophil and carbopol polymers
1 ... 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 ... 290